Clinical Trials Logo

Endovascular Treatment clinical trials

View clinical trials related to Endovascular Treatment.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06464731 Recruiting - Clinical trials for Endovascular Treatment

Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation

Mild-MT
Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Explore the effectiveness and safety of emergency endovascular treatment in patients with mild ischemic stroke due to acute large vessel occlusion in the anterior circulation, identified through perfusion imaging.

NCT ID: NCT06238024 Recruiting - Ischemic Stroke Clinical Trials

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

IRIS
Start date: February 2, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

NCT ID: NCT06221371 Recruiting - Clinical trials for Ischemic Stroke, Acute

Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

TNK-PLUS
Start date: December 16, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke due to middle cerebral artery (MCA) M1 or M2 occlusion.

NCT ID: NCT06179017 Recruiting - Clinical trials for Endovascular Treatment

Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion

Start date: February 7, 2024
Phase: N/A
Study type: Interventional

Exploring the Efficacy and Safety of Emergent Endovascular Treatment in Patients with Mild Ischemic Stroke Caused by Acute Anterior Circulation Large Vessel Occlusion based on Perfusion Imaging Screening

NCT ID: NCT06009146 Recruiting - Clinical trials for Endovascular Treatment

Results of Endovascular Treatment for Infrapopliteal Arterial Occlusive Disease.

Start date: July 1, 2023
Phase:
Study type: Observational

This study is a prospective, multi-center observational study, which evaluates the effectiveness and safety of endovascular therapy in the real world for infrapopliteal arterial occlusive disease from intermittent claudication to chronic threatening limb ischemia.

NCT ID: NCT05988125 Recruiting - Clinical trials for Endovascular Treatment

Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients

Start date: January 1, 2017
Phase:
Study type: Observational [Patient Registry]

To investigate the real situation of assessment, diagnosis and treatment of acute ischemic stroke patients with endovascular therapy.

NCT ID: NCT05847309 Recruiting - Clinical trials for Acute Ischemic Stroke

Early vs Delayed Extubation After Endovascular Treatment for Acute Ischemic Stroke

EDESTROKE
Start date: April 18, 2023
Phase: N/A
Study type: Interventional

Although older studies, most of them retrospective in design, advocated sedation over general anesthesia during endovascular treatment for acute ischemic stroke, a recent meta-analysis and randomized studies have shown that general anesthesia is associated with better functional status at 3 months compared with local anesthesia and sedation. In our center, most procedures are performed under general anesthesia, and once the procedure is complete, the patient is transferred intubated and sedated to the ICU. If the patient is hemodynamically and respiratory stable, the patient will be extubated, and will be discharged to the Neurology hospitalization floor. Several factors have been described that may influence the evolution and functional status at three months of patients who have suffered a stroke and have received endovascular treatment, such as the time between the onset of symptoms and admission to the ward for performing the procedure, the use of general anesthesia compared to sedation and local anesthesia, adequate control of blood pressure, the size of the cerebral infarct, or a worse neurological examination at the time of the procedure. In turn, several factors have been described that may influence the success of extubation in a patient who has suffered an acute ischemic stroke and who has required orotracheal intubation, such as the absence of dysarthria, the size of the infarct, the location of the infarction, the NIHSS (National Institutes of health Stroke Scale) or neurological status prior to orotracheal intubation. The investigators do not know, however, whether the time of mechanical ventilation can influence the evolution and functional status at three months of patients who have suffered a stroke and have received endovascular treatment under general anesthesia

NCT ID: NCT05631847 Recruiting - Clinical trials for Acute Ischemic Stroke

Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke

BEST-BAO
Start date: April 17, 2023
Phase: N/A
Study type: Interventional

Two recent randomized controlled trials (BAOCHE and ATTENTION) have confirmed the efficacy and safety of endovascular therapy in patient with acute ischemic stroke (AIS) due to basilar artery occlusion (BAO). However, it is still inconclusive whether there is any differences between endovascular therapy with or without bridging intravenous thrombolysis in acute BAO. So far, no randomized controlled trial has been conducted specifically for endovascular therapy with or without intravenous thrombolysis for ischemic stroke due to BAO. Therefore, this study plans to conduct a prospective, multicenter, randomized controlled trial to compare the functional outcomes between endovascular therapy with and without intravenous thrombolysis in patient with AIS due to BAO. This study is a multicenter, parallel, open label, randomized controlled trial comparing direct endovascular therapy versus endovascular therapy bridging intravenous thrombolysis (IVT). This study intends to include patients with AIS due to BAO fulfilling the following inclusion criteria: patients with AIS caused by BAO confirmed by CTA/MRA/DSA; IVT can be started within 4.5 hours after symptoms onset; Age ≥ 18 years old; NIHSS score ≥ 6. The main outcome is the 3-month mRS scale score. Secondary outcomes included NIHSS at 24 hours and 7 days after surgery, CTA vascular recanalization at 24-72 hours, mRS at 5-7 days, and infarct volume. The safety outcomes included 90-day mortality and the incidence of sICH.

NCT ID: NCT05615038 Recruiting - Clinical trials for Endovascular Treatment

A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion

ANGEL-COAST
Start date: November 7, 2022
Phase: N/A
Study type: Interventional

Compare the effectiveness and safety of contact aspiration (CA) and stent retriever (SR) in acute ischemic stroke patients with basilar artery occlusion.

NCT ID: NCT05512910 Recruiting - Clinical trials for Ischemic Stroke, Acute

Minocycline for Acute Ischemic Stroke Undergoing Endovascular Treatment Due to Basilar Artery Occlusion (MIST-B)

MIST-B
Start date: December 13, 2022
Phase: Phase 4
Study type: Interventional

This is a prospective, randomized, open-label, evaluator-blinded, single center, proof of concept trial to explore possible beneficial effect of minocycline on acute ischemic stroke (AIS) undergoing endovascular treatment due to basilar artery occlusion (BAO). Minocycline has excellent safety profiles, have been previously demonstrated individually to reduce infarction in animal models of stroke, and have potentially mechanisms of antioxidant, anti-inflammatory, anti-apoptotic and protection of blood-brain barrier. However, it is not known whether minocycline can reduce futile recanalization of endovascular treatment, and improve the outcome of patients with AIS due to BAO. Eligible and willing subjects will be randomly assigned to the treatment group or the control group. The treatment group will receive 200 mg oral minocycline within three hours prior to successful reperfusion, followed by 100 mg every 12 hours times for a total of 5 days. Both groups will receive endovascular thrombectomy and standard medical. The treatment with minocycline will start as soon as possible after diagnosis of stroke. Measures of stroke severity and disability will be recorded at baseline and through the follow-up periods (90 days). The evaluator will be blind to the allocation of patients further minimizing the bias.